ENDPOINTS NEWS2h
End of obe­si­ty drug short­age threat­ens pa­tient ac­cess to com­pound­ed shots that Lil­ly calls risky
Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...
ENDPOINTS NEWS2h
UK gov­ern­ment pro­pos­es phased roll­out of Eli Lil­ly's weight loss drug
The UK’s publicly funded healthcare system has proposed phasing its rollout of Eli Lilly’s weight loss treatment tirzepatide ...
ENDPOINTS NEWS3h
WuXi com­pa­nies may sell units im­pact­ed by Biose­cure — re­port
WuXi AppTec and WuXi Biologics are reportedly looking to sell part of their operations that have struggled because of ...
ENDPOINTS NEWS4h
FDA's drug cen­ter launch­es new co­or­di­nat­ing body for mod­el­ing and sim­u­la­tion
The FDA's Center for Drug Evaluation and Research on Wednesday officially launched a new center of excellence to better ...
ENDPOINTS NEWS6h
Flag­ship part­ners with key Sin­ga­pore R&D agency as it boosts APAC in­vest­ment
Flagship Pioneering's roots in Singapore are growing less than a year after the biotech incubator first unveiled its ...
ENDPOINTS NEWS6h
Op­di­vo gets FDA ap­proval for use around lung can­cer surgery fol­low­ing Keytru­da and Imfinzi
The FDA greenlighted Bristol Myers Squibb’s Opdivo for use before and after surgery for non-small cell lung cancer. A regimen ...
ENDPOINTS NEWS5h
No­vo and Lil­ly out­line plans to mit­i­gate dis­rup­tions from US port strikes
Novo Nordisk and Eli Lilly, whose obesity drugs are some of the most in-demand drugs in the US, have drafted plans to avoid ...
ENDPOINTS NEWS15h
In­vestor Kur­ma Part­ners rais­es €140M for lat­est Eu­rope-fo­cused biotech fund
Kurma Partners has closed the first part of its latest biotech-focused fund, following a pair of M&A exits for drug ...
ENDPOINTS NEWS11h
Eli Lil­ly re­solves short­age for tirzepatide, end­ing com­pounder­s' run
Eli Lilly’s blockbuster GLP-1 drug tirzepatide is finally back on track in the US after two years of intermittent shortages ...
ENDPOINTS NEWS14h
Enara Bio’s $32.5M Se­ries B to sup­port lead dark anti­gen pro­gram for GI can­cers
Enara Bio has snagged $32.5 million in a Series B fundraise, backed in part by Pfizer’s venture arm, to help develop a ...
ENDPOINTS NEWS6h
Pfiz­er lays off staff in Ire­land; Bax­ter clos­es NC fa­cil­i­ty due to hur­ri­cane dam­age
Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, ...
ENDPOINTS NEWS22h
Septer­na files for Nas­daq list­ing as biotech IPOs come to life
Septerna is joining biotech's IPO on-deck circle, preparing for a public offering with two other startups that have recently ...